Literature DB >> 6238829

Effects of zimeldine, mianserin and amitriptyline on psychomotor skills and their interaction with ethanol a placebo controlled cross-over study.

T Seppälä, C Strömberg, I Bergman.   

Abstract

13 healthy volunteers participated in a double-blind, four-period, cross-over study. In each period, the trial drugs (placebo, zimeldine, amitriptyline and mianserin) were given in fixed dosages for 8 days; amitriptyline 10-50 mg twice daily, mianserin 10-30 mg twice daily and zimeldine 200 mg once daily. Ethanol 1 g/kg bodyweight was drunk 2 hours after drug intake on Days 1 and 8 of each period, the latter being separated by a 2 week wash-out period. Ratings of subjective feelings and side effects, and performance tests were done on Days 1 and 8 of each period before, 1.5, 3 and 4.5 h after drug intake, i.e. 2 of the tests were performed under the influence of ethanol. Mianserin decreased critical flicker frequency, slowed reactions under discriminative stimulation and tended to cause nystagmus, but only on Day 1 (after the first 10 mg dose). Amitriptyline impaired coordination on Days 1 (after the initial 10 mg dose) and 8, and lowered the flicker threshold on Day 8 at "steady state" (after the 50 mg morning dose). Both these antidepressants were felt to be sedative, especially in the initial phase of the treatment, and they interacted additively with ethanol. No impairment of psychomotor skills was associated with zimeldine, only a subjective sedative effect of the 200 mg dose was seen on Day 1. Zimeldine did not enhance the effects of ethanol; it even showed some antagonism of ethanol-induced body sway in the standing steadiness test. In contrast to amitriptyline and mianserin, zimeldine was regarded as not harming psychomotor skills, and as not having any observable interaction with ethanol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6238829     DOI: 10.1007/bf00544043

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  39 in total

1.  Effects of m-xylene on human equilibrium measured with a quantitative method.

Authors:  K Savolainen; M Linnavuo
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-04

2.  Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man.

Authors:  K Aranko; M J Mattila; T Seppälä
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

3.  Inhibition of 5-hydroxytryptamine and noradrenaline uptake in platelets and synaptosomes incubated in plasma from human subjects treated with amitryptyline or nortriptyline: utilization of the principle for a bioassay method.

Authors:  J Tuomisto; E Tukiainen; R Voutilainen; P Tuomainen
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

4.  Repeated-measures latin square designs in clinical pharmacology.

Authors:  W H Wilson; T A Ban
Journal:  Methods Find Exp Clin Pharmacol       Date:  1982

5.  Zimelidine: a therapeutic and pharmacokinetic study in depression.

Authors:  A Coppen; V A Ramo Rao; C Swade; K Wood
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

6.  Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z)- and (E)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl) allylamines and their secondary analogues.

Authors:  S B Ross; A L Renyi
Journal:  Neuropharmacology       Date:  1977-01       Impact factor: 5.250

7.  Histamine-induced arousal in the conscious and pentobarbital-pretreated rat.

Authors:  P W Kalivas
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

8.  Psychomotor skills in depressed out-patients treated with L-tryptophan, doxepin, or chlorimipramine.

Authors:  T Seppälä; M Linnoila; M J Mattila
Journal:  Ann Clin Res       Date:  1978-08

9.  Tofisopam, a novel 3,4-benzodiazepine: multiple-dose effects on psychomotor skills and memory. Comparison with diazepam and interactions with ethanol.

Authors:  T Seppälä; E Palva; M J Mattila; K Korttila; R C Shrotriya
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

10.  Effects of amitriptyline and zimelidine in combination with ethanol.

Authors:  D B Scott; D Fagan; B Tiplady
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more
  7 in total

Review 1.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

2.  Echocardiographic and psychometric effects of amitriptyline or imipramine plus alcohol.

Authors:  C Strömberg; A Suokas; T Seppälä; M Kupari
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Effects of a sauna on the pharmacokinetics and pharmacodynamics of midazolam and ephedrine in healthy young women.

Authors:  J Vanakoski; C Strömberg; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men.

Authors:  M Siepmann; S Krause; P Joraschky; M Mück-Weymann; W Kirch
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

5.  Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects.

Authors:  I Berlin; A Cournot; R Zimmer; A M Pedarriosse; R Manfredi; P Molinier; A J Puech
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Interaction of alcohol with maprotiline or nomifensine: echocardiographic and psychometric effects.

Authors:  C Strömberg; A Suokas; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Acute effects of amitriptyline on human performance and interactions with diazepam.

Authors:  A Patat; M J Klein; M Hucher; J Granier
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.